Andere talen Prelude Therapeutics Incorporated

Aandelen

PRLD

US74065P1012

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,73 ^USD	-1,06%		-3,62%	-12,65%

10/04	Bryant D. Lim wordt financieel directeur en boekhoudkundig directeur van Prelude Therapeutics Incorporated	CI
13/03	Transcript : Prelude Therapeutics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	10/04
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	10/04
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting	09/04
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting	05/03
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference	29/02
Prelude Therapeutics Shares Surge Following Shelf Registration	16/02
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024	15/02
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index	15/12
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding	13/12
Prelude Therapeutics Announces $25 Million Private Placement	11/12
Prelude Therapeutics Incorporated : Announces $25 Million Private Placement - Form 8-K	11/12
Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding	11/12
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results	01/11
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology	01/11
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology	01/11
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	14-10-23
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	14-10-23
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	14-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Prelude Therapeutics Incorporated

Aandelen

PRLD

US74065P1012

Andere talen

Filters